SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Imara Reports Will Present Interim Data From Ongoing Phase 2a Study Of IMR-687 In Patients With Sickle Cell Disease At European Hematology Association Meeting Jun. 11-12, 2020

Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today

Benzinga · 05/21/2020 11:16

Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it will present interim data from the ongoing Phase 2a study of IMR-687 in patients with sickle cell disease at the 25th Annual European Hematology Association (EHA) Congress to be held virtually June 11-21, 2020.

The data will be presented by Biree Andemariam, M.D., Associate Professor at UConn School of Medicine and Director of the New England Sickle Cell Institute at UConn Health, and lead investigator for the trial. Dr. Andemariam’s presentation (Abstract #S290), titled “IMR-687, A Highly Selective Phosphodiesterase 9 Inhibitor (PDE9I), Increases F-Cells and Fetal Hemoglobin in a Ph-2A Interim Analysis” will be included in the oral abstract session, “New Therapeutic Approaches for Sickle Cell Disease.” The presentation will be available for on-demand viewing starting at 2:30 a.m. ET / 8:30 a.m. CEST on Friday, June 12, 2020, and will be accessible until October 15, 2020.

In January 2020, Imara completed enrollment in the IMR-687 Phase 2a clinical trial in sickle cell patients and the Company plans to report top-line data from the trial in the fourth quarter of 2020.